Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
This study is ongoing, but not recruiting participants.
Sponsor:
Boehringer Ingelheim Pharmaceuticals
Information provided by (Responsible Party):
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01431274
First received: September 8, 2011
Last updated: May 15, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Disease, Chronic Obstructive |
Drug: tiotropium + olodaterol Drug: tiotropium Drug: olodaterol |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1] |
Resource links provided by NLM:
MedlinePlus related topics:
COPD (Chronic Obstructive Pulmonary Disease)
Drug Information available for:
Tiotropium bromide
U.S. FDA Resources
Further study details as provided by Boehringer Ingelheim Pharmaceuticals:
Primary Outcome Measures:
- FEV1 AUC0-3h response [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Trough FEV1 response [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- SGRQ total score (This endpoint will be evaluated after combining the data from this and the replicate study 1237.6) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- TDI focal score (Key secondary endpoint; This endpoint will be evaluated after combining the data from this and the replicate study 1237.6) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- FVC AUC0-3h response [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Trough FVC response [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- FEV1 AUC0-12h response [L] in sub-set of patients with 12-hour PFTs [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- FVC AUC0-12h response [L] in sub-set of patients with 12-hour PFTs [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- FEV1 peak0-3h response [L] [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- FVC peak0-3h response [L] [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 2624 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | September 2013 |
| Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: tiotropium+olodaterol low dose FDC
Once daily 2 puffs solution for inhalation Respimat
|
Drug: tiotropium + olodaterol
fixed dose combination
|
|
Experimental: tiotropium+olodaterol high dose FDC
Once daily 2 puffs solution for inhalation Respimat
|
Drug: tiotropium + olodaterol
fixed dose combination
|
|
Active Comparator: olodaterol
Once daily 2 puffs solution for inhalation Respimat
|
Drug: olodaterol
one dose only
|
|
Active Comparator: tiotropium low dose
Once daily 2 puffs solution for inhalation Respimat
|
Drug: tiotropium
low dose
|
|
Active Comparator: tiotropium high dose
Once daily 2 puffs solution for inhalation Respimat
|
Drug: tiotropium
high dose
|
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Diagnosis of chronic obstructive pulmonary disease.
- Relatively stable airway obstruction with post FEV1< 80% predicted normal and post FEV1/FVC <70%.
- Male or female patients, 40 years of age or older.
- Smoking history of more than 10 pack years.
Exclusion criteria:
- Significant disease other than COPD
- Clinically relevant abnormal lab values.
- History of asthma.
- Diagnosis of thyrotoxicosis
- Diagnosis of paroxysmal tachycardia
- History of myocardial infarction within 1 year of screening visit
- Unstable or life-threatening cardiac arrhythmia.
- Hospitalization for heart failure within the past year.
- Known active tuberculosis.
- Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years
- History of life-threatening pulmonary obstruction.
- History of cystic fibrosis.
- Clinically evident bronchiectasis.
- History of significant alcohol or drug abuse.
- Thoracotomy with pulmonary resection
- Oral ß-adrenergics.
- Oral corticosteroid medication at unstable doses
- Regular use of daytime oxygen therapy for more than one hour per day
- Pulmonary rehabilitation program in the six weeks prior to the screening visit
- Investigational drug within one month or six half lives (whichever is greater) prior to screening visit
- Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA
- Pregnant or nursing women.
- Women of childbearing potential not using a highly effective method of birth control
- Patients who are unable to comply with pulmonary medication restrictions
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01431274
Hide Study Locations
Hide Study LocationsLocations
| United States, Alabama | |
| 1237.5.01038 Boehringer Ingelheim Investigational Site | |
| Jasper, Alabama, United States | |
| 1237.5.01036 Boehringer Ingelheim Investigational Site | |
| Mobile, Alabama, United States | |
| United States, Colorado | |
| 1237.5.01015 Boehringer Ingelheim Investigational Site | |
| Boulder, Colorado, United States | |
| 1237.5.01024 Boehringer Ingelheim Investigational Site | |
| Wheat Ridge, Colorado, United States | |
| United States, Connecticut | |
| 1237.5.01034 Boehringer Ingelheim Investigational Site | |
| Stamford, Connecticut, United States | |
| United States, Florida | |
| 1237.5.01003 Boehringer Ingelheim Investigational Site | |
| Clearwater, Florida, United States | |
| 1237.5.01010 Boehringer Ingelheim Investigational Site | |
| Clearwater, Florida, United States | |
| 1237.5.01027 Boehringer Ingelheim Investigational Site | |
| Panama City, Florida, United States | |
| United States, Illinois | |
| 1237.5.01031 Boehringer Ingelheim Investigational Site | |
| O'Fallon, Illinois, United States | |
| United States, Louisiana | |
| 1237.5.01035 Boehringer Ingelheim Investigational Site | |
| Opelousas, Louisiana, United States | |
| 1237.5.01004 Boehringer Ingelheim Investigational Site | |
| Shreveport, Louisiana, United States | |
| United States, Maine | |
| 1237.5.01017 Boehringer Ingelheim Investigational Site | |
| Biddeford, Maine, United States | |
| United States, Maryland | |
| 1237.5.01028 Boehringer Ingelheim Investigational Site | |
| Columbia, Maryland, United States | |
| United States, Michigan | |
| 1237.5.01013 Boehringer Ingelheim Investigational Site | |
| Livonia, Michigan, United States | |
| United States, Nebraska | |
| 1237.5.01019 Boehringer Ingelheim Investigational Site | |
| Omaha, Nebraska, United States | |
| United States, New York | |
| 1237.5.01025 Boehringer Ingelheim Investigational Site | |
| Larchmont, New York, United States | |
| 1237.5.01008 Boehringer Ingelheim Investigational Site | |
| Rochester, New York, United States | |
| United States, North Carolina | |
| 1237.5.01023 Boehringer Ingelheim Investigational Site | |
| Raleigh, North Carolina, United States | |
| 1237.5.01016 Boehringer Ingelheim Investigational Site | |
| Tabor City, North Carolina, United States | |
| United States, Ohio | |
| 1237.5.01039 Boehringer Ingelheim Investigational Site | |
| Centerville, Ohio, United States | |
| 1237.5.01006 Boehringer Ingelheim Investigational Site | |
| Cincinnati, Ohio, United States | |
| 1237.5.01040 Boehringer Ingelheim Investigational Site | |
| Columbus, Ohio, United States | |
| 1237.5.01037 Boehringer Ingelheim Investigational Site | |
| Toledo, Ohio, United States | |
| United States, Oklahoma | |
| 1237.5.01009 Boehringer Ingelheim Investigational Site | |
| Oklahoma City, Oklahoma, United States | |
| United States, Pennsylvania | |
| 1237.5.01032 Boehringer Ingelheim Investigational Site | |
| Charleston, Pennsylvania, United States | |
| United States, Rhode Island | |
| 1237.5.01005 Boehringer Ingelheim Investigational Site | |
| Johnston, Rhode Island, United States | |
| United States, South Carolina | |
| 1237.5.01021 Boehringer Ingelheim Investigational Site | |
| Easley, South Carolina, United States | |
| 1237.5.01012 Boehringer Ingelheim Investigational Site | |
| Gaffney, South Carolina, United States | |
| 1237.5.01014 Boehringer Ingelheim Investigational Site | |
| Spartanburg, South Carolina, United States | |
| United States, Texas | |
| 1237.5.01029 Boehringer Ingelheim Investigational Site | |
| Ft. Worth, Texas, United States | |
| 1237.5.01002 Boehringer Ingelheim Investigational Site | |
| San Antonio, Texas, United States | |
| United States, Virginia | |
| 1237.5.01026 Boehringer Ingelheim Investigational Site | |
| Lynchburg, Virginia, United States | |
| United States, Washington | |
| 1237.5.01007 Boehringer Ingelheim Investigational Site | |
| Spokane, Washington, United States | |
| 1237.5.01033 Boehringer Ingelheim Investigational Site | |
| Tacoma, Washington, United States | |
| United States, West Virginia | |
| 1237.5.01001 Boehringer Ingelheim Investigational Site | |
| Morgantown, West Virginia, United States | |
| Argentina | |
| 1237.5.54010 Boehringer Ingelheim Investigational Site | |
| Buenos Aires, Argentina | |
| 1237.5.54016 Boehringer Ingelheim Investigational Site | |
| Caba, Argentina | |
| 1237.5.54013 Boehringer Ingelheim Investigational Site | |
| Caba, Argentina | |
| 1237.5.54003 Boehringer Ingelheim Investigational Site | |
| Capital Federal, Argentina | |
| 1237.5.54002 Boehringer Ingelheim Investigational Site | |
| Cuidad Autonoma de Buenos Airess A, Argentina | |
| 1237.5.54006 Boehringer Ingelheim Investigational Site | |
| Mar del Plata, Argentina | |
| 1237.5.54007 Boehringer Ingelheim Investigational Site | |
| Mar del Plata, Argentina | |
| 1237.5.54009 Boehringer Ingelheim Investigational Site | |
| Mendoza, Argentina | |
| 1237.5.54012 Boehringer Ingelheim Investigational Site | |
| Monte Grande, Argentina | |
| 1237.5.54008 Boehringer Ingelheim Investigational Site | |
| Quilmes, Argentina | |
| 1237.5.54005 Boehringer Ingelheim Investigational Site | |
| Rosario, Argentina | |
| 1237.5.54004 Boehringer Ingelheim Investigational Site | |
| San Miguel de Tucuma, Argentina | |
| 1237.5.54011 Boehringer Ingelheim Investigational Site | |
| San Miguel de Tucuman, Argentina | |
| Australia, South Australia | |
| 1237.5.61001 Boehringer Ingelheim Investigational Site | |
| Toorak Gardens, South Australia, Australia | |
| 1237.5.61002 Boehringer Ingelheim Investigational Site | |
| Woodville, South Australia, Australia | |
| Australia, Victoria | |
| 1237.5.61004 Boehringer Ingelheim Investigational Site | |
| Frankston, Victoria, Australia | |
| Bulgaria | |
| 1237.5.35905 Boehringer Ingelheim Investigational Site | |
| Plovdiv, Bulgaria | |
| 1237.5.35901 Boehringer Ingelheim Investigational Site | |
| Rousse, Bulgaria | |
| 1237.5.35906 Boehringer Ingelheim Investigational Site | |
| Shumen, Bulgaria | |
| 1237.5.35904 Boehringer Ingelheim Investigational Site | |
| Sofia, Bulgaria | |
| 1237.5.35902 Boehringer Ingelheim Investigational Site | |
| Sofia, Bulgaria | |
| 1237.5.35903 Boehringer Ingelheim Investigational Site | |
| Troyan, Bulgaria | |
| 1237.5.35908 Boehringer Ingelheim Investigational Site | |
| Veliko Tarnovo, Bulgaria | |
| Canada, Alberta | |
| 1237.5.02002 Boehringer Ingelheim Investigational Site | |
| Calgary, Alberta, Canada | |
| Canada, British Columbia | |
| 1237.5.02001 Boehringer Ingelheim Investigational Site | |
| Vancouver, British Columbia, Canada | |
| Canada, Manitoba | |
| 1237.5.02004 Boehringer Ingelheim Investigational Site | |
| Winnipeg, Manitoba, Canada | |
| Canada, Ontario | |
| 1237.5.02005 Boehringer Ingelheim Investigational Site | |
| Burlington, Ontario, Canada | |
| 1237.5.02007 Boehringer Ingelheim Investigational Site | |
| Grimsby, Ontario, Canada | |
| 1237.5.02011 Boehringer Ingelheim Investigational Site | |
| Ottawa, Ontario, Canada | |
| Canada, Quebec | |
| 1237.5.02008 Boehringer Ingelheim Investigational Site | |
| Sherbrooke, Quebec, Canada | |
| Canada, Saskatchewan | |
| 1237.5.02009 Boehringer Ingelheim Investigational Site | |
| Saskatoon, Saskatchewan, Canada | |
| Canada | |
| 1237.5.02003 Boehringer Ingelheim Investigational Site | |
| Quebec, Canada | |
| 1237.5.02006 Boehringer Ingelheim Investigational Site | |
| Quebec, Canada | |
| China | |
| 1237.5.86003 Boehringer Ingelheim Investigational Site | |
| Beijing, China | |
| 1237.5.86004 Boehringer Ingelheim Investigational Site | |
| Beijing, China | |
| 1237.5.86011 Boehringer Ingelheim Investigational Site | |
| Changsha, China | |
| 1237.5.86012 Boehringer Ingelheim Investigational Site | |
| Changsha, China | |
| 1237.5.86014 Boehringer Ingelheim Investigational Site | |
| Foshan, China | |
| 1237.5.86001 Boehringer Ingelheim Investigational Site | |
| Guangzhou, China | |
| 1237.5.86015 Boehringer Ingelheim Investigational Site | |
| Nan Ning, China | |
| 1237.5.86005 Boehringer Ingelheim Investigational Site | |
| Shanghai, China | |
| 1237.5.86006 Boehringer Ingelheim Investigational Site | |
| Shanghai, China | |
| 1237.5.86007 Boehringer Ingelheim Investigational Site | |
| Shanghai, China | |
| 1237.5.86002 Boehringer Ingelheim Investigational Site | |
| Shanghai, China | |
| 1237.5.86009 Boehringer Ingelheim Investigational Site | |
| Shenyang, China | |
| 1237.5.86016 Boehringer Ingelheim Investigational Site | |
| Wuhan, China | |
| 1237.5.86010 Boehringer Ingelheim Investigational Site | |
| Xi'An, China | |
| 1237.5.86008 Boehringer Ingelheim Investigational Site | |
| Yangzhou, China | |
| 1237.5.86017 Boehringer Ingelheim Investigational Site | |
| Yinchuan, China | |
| Czech Republic | |
| 1237.5.42004 Boehringer Ingelheim Investigational Site | |
| Beroun, Czech Republic | |
| 1237.5.42002 Boehringer Ingelheim Investigational Site | |
| Cvikov, Czech Republic | |
| 1237.5.42001 Boehringer Ingelheim Investigational Site | |
| Praha 6, Czech Republic | |
| 1237.5.42005 Boehringer Ingelheim Investigational Site | |
| Rokycany, Czech Republic | |
| 1237.5.42003 Boehringer Ingelheim Investigational Site | |
| Znojmo, Czech Republic | |
| Denmark | |
| 1237.5.45002 Boehringer Ingelheim Investigational Site | |
| Aalborg, Denmark | |
| 1237.5.45009 Boehringer Ingelheim Investigational Site | |
| Hvidovre, Denmark | |
| 1237.5.45007 Boehringer Ingelheim Investigational Site | |
| Kolding, Denmark | |
| 1237.5.45001 Boehringer Ingelheim Investigational Site | |
| København NV, Denmark | |
| 1237.5.45011 Boehringer Ingelheim Investigational Site | |
| Næstved, Denmark | |
| 1237.5.45006 Boehringer Ingelheim Investigational Site | |
| Odense C, Denmark | |
| 1237.5.45008 Boehringer Ingelheim Investigational Site | |
| Roskilde, Denmark | |
| 1237.5.45010 Boehringer Ingelheim Investigational Site | |
| Rungsted Kyst, Denmark | |
| 1237.5.45003 Boehringer Ingelheim Investigational Site | |
| Silkeborg, Denmark | |
| 1237.5.45005 Boehringer Ingelheim Investigational Site | |
| Sønderborg, Denmark | |
| 1237.5.45004 Boehringer Ingelheim Investigational Site | |
| Vaerløse, Denmark | |
| Estonia | |
| 1237.5.37002 Boehringer Ingelheim Investigational Site | |
| Tallin, Estonia | |
| 1237.5.37001 Boehringer Ingelheim Investigational Site | |
| Tartu, Estonia | |
| Finland | |
| 1237.5.35801 Boehringer Ingelheim Investigational Site | |
| Helsinki, Finland | |
| 1237.5.35804 Boehringer Ingelheim Investigational Site | |
| Pori, Finland | |
| 1237.5.35802 Boehringer Ingelheim Investigational Site | |
| Turku, Finland | |
| France | |
| 1237.5.33004 Boehringer Ingelheim Investigational Site | |
| Bethune Cedex, France | |
| 1237.5.33007 Boehringer Ingelheim Investigational Site | |
| Montpellier cedex 5, France | |
| 1237.5.33005 Boehringer Ingelheim Investigational Site | |
| Nantes, France | |
| 1237.5.33006 Boehringer Ingelheim Investigational Site | |
| Nîmes cedex 9, France | |
| 1237.5.33008 Boehringer Ingelheim Investigational Site | |
| Perpignan, France | |
| 1237.5.33001 Boehringer Ingelheim Investigational Site | |
| Saint Pierre Cedex, France | |
| 1237.5.33002 Boehringer Ingelheim Investigational Site | |
| Strasbourg, France | |
| Germany | |
| 1237.5.49006 Boehringer Ingelheim Investigational Site | |
| Bamberg, Germany | |
| 1237.5.49013 Boehringer Ingelheim Investigational Site | |
| Berlin, Germany | |
| 1237.5.49002 Boehringer Ingelheim Investigational Site | |
| Berlin, Germany | |
| 1237.5.49003 Boehringer Ingelheim Investigational Site | |
| Berlin, Germany | |
| 1237.5.49011 Boehringer Ingelheim Investigational Site | |
| Erfurt, Germany | |
| 1237.5.49005 Boehringer Ingelheim Investigational Site | |
| Hamburg, Germany | |
| 1237.5.49010 Boehringer Ingelheim Investigational Site | |
| Hamburg, Germany | |
| 1237.5.49009 Boehringer Ingelheim Investigational Site | |
| Koblenz, Germany | |
| 1237.5.49014 Boehringer Ingelheim Investigational Site | |
| Neu-Isenburg, Germany | |
| 1237.5.49012 Boehringer Ingelheim Investigational Site | |
| Oschersleben, Germany | |
| 1237.5.49001 Boehringer Ingelheim Investigational Site | |
| Rüdersdorf, Germany | |
| 1237.5.49004 Boehringer Ingelheim Investigational Site | |
| Weinheim, Germany | |
| 1237.5.49008 Boehringer Ingelheim Investigational Site | |
| Wiesloch, Germany | |
| Guatemala | |
| 1237.5.50201 Boehringer Ingelheim Investigational Site | |
| Guatemala, Guatemala | |
| 1237.5.50202 Boehringer Ingelheim Investigational Site | |
| Guatemala, Guatemala | |
| 1237.5.50203 Boehringer Ingelheim Investigational Site | |
| Guatemala, Guatemala | |
| 1237.5.50204 Boehringer Ingelheim Investigational Site | |
| Guatemala, Guatemala | |
| 1237.5.50205 Boehringer Ingelheim Investigational Site | |
| Guatemala, Guatemala | |
| 1237.5.50206 Boehringer Ingelheim Investigational Site | |
| Guatemala, Guatemala | |
| 1237.5.50207 Boehringer Ingelheim Investigational Site | |
| Guatemala, Guatemala | |
| Hungary | |
| 1237.5.36005 Boehringer Ingelheim Investigational Site | |
| Debrecen, Hungary | |
| 1237.5.36001 Boehringer Ingelheim Investigational Site | |
| Deszk, Hungary | |
| 1237.5.36006 Boehringer Ingelheim Investigational Site | |
| Kapuvar, Hungary | |
| 1237.5.36003 Boehringer Ingelheim Investigational Site | |
| Szombathely, Hungary | |
| 1237.5.36002 Boehringer Ingelheim Investigational Site | |
| Törökbalint, Hungary | |
| India | |
| 1237.5.91010 Boehringer Ingelheim Investigational Site | |
| Ahmedabad, India | |
| 1237.5.91002 Boehringer Ingelheim Investigational Site | |
| Bangalore, India | |
| 1237.5.91007 Boehringer Ingelheim Investigational Site | |
| Bangalore, India | |
| 1237.5.91004 Boehringer Ingelheim Investigational Site | |
| Coimbatore, India | |
| 1237.5.91011 Boehringer Ingelheim Investigational Site | |
| Hyderabad, India | |
| 1237.5.91001 Boehringer Ingelheim Investigational Site | |
| Jaipur, India | |
| 1237.5.91008 Boehringer Ingelheim Investigational Site | |
| Jaipur, India | |
| 1237.5.91009 Boehringer Ingelheim Investigational Site | |
| Mysore, India | |
| 1237.5.91006 Boehringer Ingelheim Investigational Site | |
| Pune, India | |
| Italy | |
| 1237.5.39008 Boehringer Ingelheim Investigational Site | |
| Cagliari, Italy | |
| 1237.5.39002 Boehringer Ingelheim Investigational Site | |
| Genova, Italy | |
| 1237.5.39006 Boehringer Ingelheim Investigational Site | |
| Montescano (PV), Italy | |
| 1237.5.39009 Boehringer Ingelheim Investigational Site | |
| Monza, Italy | |
| 1237.5.39004 Boehringer Ingelheim Investigational Site | |
| Parma, Italy | |
| 1237.5.39001 Boehringer Ingelheim Investigational Site | |
| Pisa, Italy | |
| Japan | |
| 1237.5.81003 Boehringer Ingelheim Investigational Site | |
| Aoba-ku, Sendai, Miyagi, Japan | |
| 1237.5.81001 Boehringer Ingelheim Investigational Site | |
| Asahikawa, Hokkaido, Japan | |
| 1237.5.81006 Boehringer Ingelheim Investigational Site | |
| Bunkyo-ku, Tokyo, Japan | |
| 1237.5.81044 Boehringer Ingelheim Investigational Site | |
| Chuo-ku, Kumamoto, Kumamoto, Japan | |
| 1237.5.81035 Boehringer Ingelheim Investigational Site | |
| Gifu, Gifu, Japan | |
| 1237.5.81017 Boehringer Ingelheim Investigational Site | |
| Hakata-ku, Fukuoka, Fukuoka, Japan | |
| 1237.5.81031 Boehringer Ingelheim Investigational Site | |
| Hamamatsushi, Shizuoka, Japan | |
| 1237.5.81014 Boehringer Ingelheim Investigational Site | |
| Himeji, Hyogo, Japan | |
| 1237.5.81037 Boehringer Ingelheim Investigational Site | |
| Ikoma, Nara, Japan | |
| 1237.5.81024 Boehringer Ingelheim Investigational Site | |
| Inashiki-gun, Ibaraki, Japan | |
| 1237.5.81008 Boehringer Ingelheim Investigational Site | |
| Itabashi-ku, Tokyo, Japan | |
| 1237.5.81016 Boehringer Ingelheim Investigational Site | |
| Jonan-ku, Fukuoka, Fukuoka, Japan | |
| 1237.5.81021 Boehringer Ingelheim Investigational Site | |
| Kagoshima, Kagoshima, Japan | |
| 1237.5.81020 Boehringer Ingelheim Investigational Site | |
| Kagoshima, Kagoshima,, Japan | |
| 1237.5.81005 Boehringer Ingelheim Investigational Site | |
| Kamogawa, Chiba, Japan | |
| 1237.5.81011 Boehringer Ingelheim Investigational Site | |
| Kishiwada, Osaka, Japan | |
| 1237.5.81018 Boehringer Ingelheim Investigational Site | |
| Kitakyusyu,Fukuoka, Japan | |
| 1237.5.81042 Boehringer Ingelheim Investigational Site | |
| Koga, Fukuoka, Japan | |
| 1237.5.81033 Boehringer Ingelheim Investigational Site | |
| Komaki, Aichi, Japan | |
| 1237.5.81032 Boehringer Ingelheim Investigational Site | |
| Komaki, Aichi, Japan | |
| 1237.5.81019 Boehringer Ingelheim Investigational Site | |
| Koshi, Kumamoto, Japan | |
| 1237.5.81027 Boehringer Ingelheim Investigational Site | |
| koto-ku, Tokyo, Japan | |
| 1237.5.81025 Boehringer Ingelheim Investigational Site | |
| Kuki, Saitama, Japan | |
| 1237.5.81038 Boehringer Ingelheim Investigational Site | |
| Kure, Hiroshima, Japan | |
| 1237.5.81015 Boehringer Ingelheim Investigational Site | |
| Kurume, Fukuoka, Japan | |
| 1237.5.81030 Boehringer Ingelheim Investigational Site | |
| Matsumoto, Nagano, Japan | |
| 1237.5.81029 Boehringer Ingelheim Investigational Site | |
| Matsumoto, Nagano, Japan | |
| 1237.5.81010 Boehringer Ingelheim Investigational Site | |
| Matsusaka, Mie, Japan | |
| 1237.5.81041 Boehringer Ingelheim Investigational Site | |
| Minami-ku. Fukuoka, Fukuoka, Japan | |
| 1237.5.81002 Boehringer Ingelheim Investigational Site | |
| Morioka, Iwate, Japan | |
| 1237.5.81036 Boehringer Ingelheim Investigational Site | |
| Nagoya, Aichi, Japan | |
| 1237.5.81034 Boehringer Ingelheim Investigational Site | |
| Nagoya, Aichi, Japan | |
| 1237.5.81004 Boehringer Ingelheim Investigational Site | |
| Naka-gun, Ibaraki, Japan | |
| 1237.5.81023 Boehringer Ingelheim Investigational Site | |
| Okinawa, Urasoe, Japan | |
| 1237.5.81022 Boehringer Ingelheim Investigational Site | |
| Okinawa, Urasoe, Japan | |
| 1237.5.81012 Boehringer Ingelheim Investigational Site | |
| Sayama, Osaka, Japan | |
| 1237.5.81045 Boehringer Ingelheim Investigational Site | |
| Sendai, Miyagi, Japan | |
| 1237.5.81009 Boehringer Ingelheim Investigational Site | |
| Seto, Aichi, Japan | |
| 1237.5.81026 Boehringer Ingelheim Investigational Site | |
| Shinagawa, Tokyo, Japan | |
| 1237.5.81007 Boehringer Ingelheim Investigational Site | |
| Shinjyuku-ku, Tokyo, Japan | |
| 1237.5.81039 Boehringer Ingelheim Investigational Site | |
| Takamatsu, Kagawa, Japan | |
| 1237.5.81040 Boehringer Ingelheim Investigational Site | |
| Takamatsu, Kagawa, Japan | |
| 1237.5.81013 Boehringer Ingelheim Investigational Site | |
| Wakayama, Wakayama, Japan | |
| 1237.5.81043 Boehringer Ingelheim Investigational Site | |
| Yanagawa-shi, Fukuoka,, Japan | |
| 1237.5.81028 Boehringer Ingelheim Investigational Site | |
| Yokohama, Kanagawa, Japan | |
| Korea, Republic of | |
| 1237.5.82004 Boehringer Ingelheim Investigational Site | |
| Bucheon, Korea, Republic of | |
| 1237.5.82008 Boehringer Ingelheim Investigational Site | |
| Daegu, Korea, Republic of | |
| 1237.5.82007 Boehringer Ingelheim Investigational Site | |
| Seoul, Korea, Republic of | |
| 1237.5.82002 Boehringer Ingelheim Investigational Site | |
| Seoul, Korea, Republic of | |
| 1237.5.82003 Boehringer Ingelheim Investigational Site | |
| Seoul, Korea, Republic of | |
| 1237.5.82001 Boehringer Ingelheim Investigational Site | |
| Seoul, Korea, Republic of | |
| 1237.5.82005 Boehringer Ingelheim Investigational Site | |
| Suwon, Korea, Republic of | |
| 1237.5.82006 Boehringer Ingelheim Investigational Site | |
| Wonju, Korea, Republic of | |
| Mexico | |
| 1237.5.52002 Boehringer Ingelheim Investigational Site | |
| Hermosillo, Mexico | |
| 1237.5.52003 Boehringer Ingelheim Investigational Site | |
| Mexico, Mexico | |
| 1237.5.52007 Boehringer Ingelheim Investigational Site | |
| Monterrey, Mexico | |
| 1237.5.52001 Boehringer Ingelheim Investigational Site | |
| Tijuana, Mexico | |
| Netherlands | |
| 1237.5.31004 Boehringer Ingelheim Investigational Site | |
| Almelo, Netherlands | |
| 1237.5.31006 Boehringer Ingelheim Investigational Site | |
| Breda, Netherlands | |
| 1237.5.31001 Boehringer Ingelheim Investigational Site | |
| Eindhoven, Netherlands | |
| 1237.5.31008 Boehringer Ingelheim Investigational Site | |
| Harderwijk, Netherlands | |
| 1237.5.31007 Boehringer Ingelheim Investigational Site | |
| Heerlen, Netherlands | |
| 1237.5.31010 Boehringer Ingelheim Investigational Site | |
| Hengelo, Netherlands | |
| 1237.5.31009 Boehringer Ingelheim Investigational Site | |
| Hoorn, Netherlands | |
| 1237.5.31005 Boehringer Ingelheim Investigational Site | |
| Nieuwegein, Netherlands | |
| 1237.5.31002 Boehringer Ingelheim Investigational Site | |
| Veldhoven, Netherlands | |
| 1237.5.31003 Boehringer Ingelheim Investigational Site | |
| Zutphen, Netherlands | |
| New Zealand | |
| 1237.5.64002 Boehringer Ingelheim Investigational Site | |
| Dunedin, New Zealand | |
| 1237.5.64001 Boehringer Ingelheim Investigational Site | |
| Greenlane East Auckland NZ, New Zealand | |
| Portugal | |
| 1237.5.35105 Boehringer Ingelheim Investigational Site | |
| Amadora, Portugal | |
| 1237.5.35101 Boehringer Ingelheim Investigational Site | |
| Coimbra, Portugal | |
| 1237.5.35104 Boehringer Ingelheim Investigational Site | |
| Lisboa, Portugal | |
| 1237.5.35102 Boehringer Ingelheim Investigational Site | |
| Lisboa, Portugal | |
| 1237.5.35103 Boehringer Ingelheim Investigational Site | |
| Porto, Portugal | |
| 1237.5.35106 Boehringer Ingelheim Investigational Site | |
| Vila Nova de Gaia, Portugal | |
| 1237.5.35107 Boehringer Ingelheim Investigational Site | |
| Viseu, Portugal | |
| Russian Federation | |
| 1237.5.07001 Boehringer Ingelheim Investigational Site | |
| Gatchina (Leningradskaya oblast), Russian Federation | |
| 1237.5.07003 Boehringer Ingelheim Investigational Site | |
| Kazan, Russian Federation | |
| 1237.5.07004 Boehringer Ingelheim Investigational Site | |
| Moscow, Russian Federation | |
| 1237.5.07005 Boehringer Ingelheim Investigational Site | |
| Moscow, Russian Federation | |
| 1237.5.07002 Boehringer Ingelheim Investigational Site | |
| St. Petersburg, Russian Federation | |
| Slovenia | |
| 1237.5.38601 Boehringer Ingelheim Investigational Site | |
| Golnik, Slovenia | |
| 1237.5.38602 Boehringer Ingelheim Investigational Site | |
| Golnik, Slovenia | |
| Turkey | |
| 1237.5.90003 Boehringer Ingelheim Investigational Site | |
| Istanbul, Turkey | |
| 1237.5.90004 Boehringer Ingelheim Investigational Site | |
| Istanbul, Turkey | |
| 1237.5.90002 Boehringer Ingelheim Investigational Site | |
| Izmir, Turkey | |
| 1237.5.90005 Boehringer Ingelheim Investigational Site | |
| Izmit, Turkey | |
| 1237.5.90001 Boehringer Ingelheim Investigational Site | |
| Mersin, Turkey | |
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Boehringer Ingelheim Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01431274 History of Changes |
| Other Study ID Numbers: | 1237.5, 2009-010668-40 |
| Study First Received: | September 8, 2011 |
| Last Updated: | May 15, 2013 |
| Health Authority: | Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica Australia: Responsible Ethics Committee Bulgaria: Bulgarian Drug Agency Canada: Health Canada China: Food and Drug Administration Czech Republic: State Institute for Drug Control Denmark: Danish Medicines Agency Estonia: The State Agency of Medicine Finland: Finnish Medicines Agency France: Agence Nationale sécurité médicament et des produits santé Germany: Federal Institute for Drugs and Medical Devices Guatemala: Ministry of Public Health and Social Assistance Hungary: National Institute of Pharmacy India: Drugs Controller General of India Italy: Ethics Committee Japan: Ministry of Health, Labor and Welfare Mexico: Federal Commission for Sanitary Risks Protection Netherlands: Central Committee Research Involving Human Subjects New Zealand: Medsafe Portugal: National Pharmacy and Medicines Institute Russia: Pharmacological Committee, Ministry of Health Slovenia: Agency for Medicinal Products - Ministry of Health South Korea: Ministry of Food and Drug Safety (MFDS) Turkey: Ministry of Health United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Chronic Disease Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Disease Attributes Pathologic Processes Respiratory Tract Diseases Tiotropium Parasympatholytics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Bronchodilator Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013